相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Characteristics of Patients With Sulphonurea-Induced Hypoglycemia
Yael Dinur Schejter et al.
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION (2012)
Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients - an analysis of the DiaRegis registry
Diethelm Tschoepe et al.
CARDIOVASCULAR DIABETOLOGY (2011)
Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study
Mohamed Hassanein et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study
S. R. Aravind et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks
Antonio R. Chacra et al.
DIABETES & VASCULAR DISEASE RESEARCH (2011)
Hypoglycemia and Cardiovascular Risks
Brian M. Frier et al.
DIABETES CARE (2011)
Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial
R. Arechavaleta et al.
DIABETES OBESITY & METABOLISM (2011)
Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial
W. Yang et al.
DIABETES OBESITY & METABOLISM (2011)
A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents
L. Olansky et al.
DIABETES OBESITY & METABOLISM (2011)
Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
A. Garber et al.
DIABETES OBESITY & METABOLISM (2011)
Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials
K. Esposito et al.
DIABETES OBESITY & METABOLISM (2011)
The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus
C. Reasner et al.
DIABETES OBESITY & METABOLISM (2011)
Drug-Induced Hypoglycaemia An Update
Chaker Ben Salem et al.
DRUG SAFETY (2011)
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes
Kaixin Zhou et al.
NATURE GENETICS (2011)
High serum ACE activity predicts severe hypoglycaemia over time in patients with type 1 diabetes
Louise Faerch et al.
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2011)
Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
Remy Boussageon et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice
M. Buysschaert et al.
DIABETES & METABOLISM (2010)
Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes
D. Williams-Herman et al.
DIABETES OBESITY & METABOLISM (2010)
Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study
Y. Iwamoto et al.
DIABETES OBESITY & METABOLISM (2010)
Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes
P. Aschner et al.
DIABETES OBESITY & METABOLISM (2010)
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study
D. R. Matthews et al.
DIABETES OBESITY & METABOLISM (2010)
Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes
K. Kaku et al.
DIABETES OBESITY & METABOLISM (2010)
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
Andre J. Scheen et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2010)
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
T. Seck et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes
Olivia J. Phung et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Hypoglycaemia with pioglitazone: analysis of data from the Prescription-Event Monitoring study
Veronika Vlckova et al.
JOURNAL OF EVALUATION IN CLINICAL PRACTICE (2010)
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
Michaela Diamant et al.
LANCET (2010)
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
Richard E. Pratley et al.
LANCET (2010)
Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin
Kjeld Hermansen et al.
PRIMARY CARE DIABETES (2010)
Pharmacogenetics in diabetes
Ewan R. Pearson
CURRENT DIABETES REPORTS (2009)
The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
Ralph A. DeFronzo et al.
DIABETES CARE (2009)
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
M. Jadzinsky et al.
DIABETES OBESITY & METABOLISM (2009)
Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin
G. Bolli et al.
DIABETES OBESITY & METABOLISM (2009)
Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial - a primary care, type 2 diabetes study
L. Blonde et al.
DIABETES OBESITY & METABOLISM (2009)
Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial
A. Schweizer et al.
DIABETES OBESITY & METABOLISM (2009)
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
E. Ferrannini et al.
DIABETES OBESITY & METABOLISM (2009)
Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
E. Bosi et al.
DIABETES OBESITY & METABOLISM (2009)
Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea
Yan Gao et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2009)
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
M. Marre et al.
DIABETIC MEDICINE (2009)
Drug-Induced Hypoglycemia: A Systematic Review
M. Hassan Murad et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus
Manuel Gonzalez-Ortiz et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2009)
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Alan Garber et al.
LANCET (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
William Duckworth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas
Georgia Ragia et al.
PHARMACOGENOMICS (2009)
Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study
Thomas J. Moretto et al.
CLINICAL THERAPEUTICS (2008)
Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France
P. Vexiau et al.
DIABETES OBESITY & METABOLISM (2008)
Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia
W. A. Scherbaum et al.
DIABETES OBESITY & METABOLISM (2008)
Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes
R. Scott et al.
DIABETES OBESITY & METABOLISM (2008)
Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2008)
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
J. C. N. Chan et al.
DIABETES OBESITY & METABOLISM (2008)
Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial
C. Pan et al.
DIABETIC MEDICINE (2008)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Anushka Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Cytochrome P450 2C9*2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus
M. L. Becker et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Serum angiotensin-converting enzyme and frequency of severe hypoglycaemia in Type 1 diabetes: does a relationship exist?
N. N. Zammitt et al.
DIABETIC MEDICINE (2007)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
K. Hermansen et al.
DIABETES OBESITY & METABOLISM (2007)
Variation in TCF7L2 influences therapeutic response to sulfonylureas -: A GoDARTs study
Ewan R. Pearson et al.
DIABETES (2007)
Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results
S. Ristic et al.
DIABETES OBESITY & METABOLISM (2007)
Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration
S. R. Heller et al.
DIABETOLOGIA (2007)
Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial
S. S. Lund et al.
DIABETES OBESITY & METABOLISM (2007)
The relationship between ACE genotype and risk of severe hypoglycaemia in a large population-based cohort of children and adolescents with type 1 diabetes
M. K. Bulsara et al.
DIABETOLOGIA (2007)
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study
A. J. Garber et al.
DIABETES OBESITY & METABOLISM (2007)
A systematic review and meta-analysis of hypoglycemia and cardiovascular event - A comparison of glyburide with other secretagogues and with insulin
Azim S. Gangji et al.
DIABETES CARE (2007)
Pharmacogenetics of glucose-lowering drug treatment - A Systematic review
Oezlem Bozkurt et al.
MOLECULAR DIAGNOSIS & THERAPY (2007)
Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes
R. Scott et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2007)
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes
Tina Vilsboll et al.
DIABETES CARE (2007)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial
M. A. Nauck et al.
DIABETES OBESITY & METABOLISM (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis:: UKPDS73
Alex D. Wright et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
I. Raz et al.
DIABETOLOGIA (2006)
Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone
S. Ristic et al.
DIABETIC MEDICINE (2006)
Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents
A Holstein et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Effect on glycernic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM
M Feinglos et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2005)
Sulfonylurea treatment of type 2 diabetes mellitus: Focus on glimepiride
MT Korytkowski
PHARMACOTHERAPY (2004)
Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone
L Jovanovic et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2004)
Effects of fluoroquinolones on insulin secretion and β-cell ATP-sensitive K+ channels
A Saraya et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients
G Schernthaner et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2004)
Repaglinide versus nateglinide monotherapy - A randomized multicenter study
J Rosenstock et al.
DIABETES CARE (2004)
Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea
A Baksi et al.
ACTA DIABETOLOGICA (2004)
Gliclazide modified release*: results of a 2-year study in patients with type 2 diabetes
P Drouin et al.
DIABETES OBESITY & METABOLISM (2004)
Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes - A population-based study of health service resource use
GP Leese et al.
DIABETES CARE (2003)
Prediction of severe hypoglycaemia by angiotensin-converting enzyme activity and genotype in Type 1 diabetes
U Pedersen-Bjergaard et al.
DIABETOLOGIA (2003)
A diabetes outcome progression trial (ADOPT)
G Viberti et al.
DIABETES CARE (2002)
Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride
M Niemi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients
G Charpentier et al.
DIABETIC MEDICINE (2001)
Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study
S Madsbad et al.
DIABETIC MEDICINE (2001)
Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus
U Pedersen-Bjergaard et al.
LANCET (2001)
Diamicron®MR once daily is effective and well tolerated in type 2 diabetes -: A double-blind, randomized, multinational study
P Drouin
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2000)
Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?
M Nattrass et al.
INTERNATIONAL JOURNAL OF OBESITY (2000)
分享论文
